10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares in Anglo-Swedish pharma major AstraZeneca jumped up by more than 3% on Friday after the presentation of Phase III results of a combination involving Lynparza (olaparib) in prostate cancer. 24 September 2021
Shares of US oncology specialist Nektar Therapeutics rose 5% to $17.10, after it announced a deal with two pharma majors to trial its investigational interleukin-15 (IL-15) receptor agonist NKTR-255. 24 September 2021
Pharmsynthez, one of Russia’s leading drugmakers, is planning to launch one of the largest productions of hormonal preparations in Russia, which will be located the city of Tyumen by November of the current year. 24 September 2021
Spanish drugmaker PharmaMar has announced its licensing partner, Specialised Therapeutics Asia (STA), has received provisional marketing approval for Zepzelca (lurbinectedin) by the Singapore Health Sciences Authority (HSA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed after prior platinum-containing chemotherapy. 24 September 2021
Japan’s Kyowa Kirin has provided new data for Crysvita (burosumab), revealing benefits for people with the rare metabolic bone disorder X-linked hypophosphatemia (XLH). 24 September 2021
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
R-Pharm, one of Russia’s leading drugmakers, has started the production of a vaccine against COVID-19 under a license from Oxford University and UK pharma major AstraZeneca, according to recent statements made by some Russian state officials and local media reports. 24 September 2021
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
UK biotech Immunocore Holdings has announced that data from a Phase III trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma (mUM) has been published in The New England Journal of Medicine (NEJM). 23 September 2021
The World Health Organization's Director General Tedros Adhanom Ghebreyesus has thanked India's Minister Mansukh Mandaviya for announcing that India will resume crucial COVID-19 vaccine shipments to COVAX in October. 23 September 2021
US biotech Novavax and its partner the Serum Institute of India today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. 23 September 2021
China’s Worg Pharmaceuticals (Hangzhou) has entered into an asset purchase agreement to acquire Belgian biotech’s Apitope International’s proprietary platform and therapeutic pipeline. 23 September 2021
Incyte Corp’s shares were down as much as 8.5% at $69.59 yesterday, despite the company receiving regulatory approval for a second drug within two days. 23 September 2021
Boston, USA-based Rhythm Pharmaceuticals has presented new data and analyses from Phase II and III trials of its candidate setmelanotide. 23 September 2021
Anglo-Swedish pharma major AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. 23 September 2021
The HER2+ breast cancer market is expected to experience low growth from $10.4 billion in 2020 to $12.1 billion in 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, China and Japan) at a compound annual growth rate (CAGR) of 1.5%. 23 September 2021
US biotech Gilead Sciences (Nasdaq: GILD) has released positive results from a Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. 23 September 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024